Tikehau Capital said yesterday that it invested approximately $29.1 million (EU €26 million) into UK-based medical device firm Medtrade Products.
Medtrade produces advanced wound care and consumer healthcare products including the Celox trauma hemostat and Foxseal occlusive dressing, according to its website.
“We are delighted to be partnering with Tikehau Capital on this next and exciting phase of our journey as a business. Medtrade is well positioned in the market and we believe Tikehau Capital will bring a wealth of capability and global connections that will only help us accelerate delivering on our mission,” Medtrade co-founder Craig Hardy said in a press release.
Tikehau said that it believes its investment will allow Medtrade to “develop a differentiated and innovative product portfolio and drive the next phase of growth.”
“Tikehau Capital’s global presence and expertise will allow Medtrade to strengthen its position across its key markets. This private equity deal is fully in line with Tikehau Capital’s strategy to reinforce its activities in the United Kingdom,” Tikehau UK head Peter Cirenza said in prepared remarks.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.